Difference between revisions of "Cost effectiveness sensitivity"
From Testiwiki
| Line 21: | Line 21: | ||
rows: | rows: | ||
[1] pcv10 | [1] pcv10 | ||
| − | [2] pcv10+19A direct effects | + | [2] pcv10 + 19A(direct effects only) |
| − | [3] | + | [3] pcv10 + 6A |
| − | [4] pcv10+19A(direct only)+6A | + | [4] pcv10 + 19A(direct only) + 6A |
| − | [5] pcv10+19A full | + | [5] pcv10 + 19A(full) |
| − | [6] pcv10+ | + | [6] pcv10 + 19A(full) + 6A = PCV13 - 3 |
columns: | columns: | ||
| − | [1] pcv13-3 | + | [1] pcv13 - 3 (excluding serotype 3) |
[2] pcv13 | [2] pcv13 | ||
| − | + | PCV13adv.inIPD price of PCV13 ICER | |
| − | + | ============== ============== =============== | |
PCV13-3 PCV13 PCV13-3 PCV13 PCV13-3 PCV13 | PCV13-3 PCV13 PCV13-3 PCV13 PCV13-3 PCV13 | ||
| − | --- --- | + | --- --- ------- ----- ----- ---- |
| − | pcv10 12 150 18 | + | pcv10 12 150 18 38 8077 8077 |
| − | pcv10+19Ad -2 134 17 | + | pcv10+19Ad -2 134 17 37 7714 7714 |
| − | pcv10+6A 50 188 25 | + | pcv10+6A 50 188 25 55 13590 13590 |
| − | pcv10+19Ad+6A 32 169 24 | + | pcv10+19Ad+6A 32 169 24 52 12724 12724 |
| − | pcv10+19Af -31 105 15 | + | pcv10+19Af -31 105 15 32 6198 6199 |
| − | pcv10+19Af+6A * 137 * | + | pcv10+19Af+6A * 137 * 43 * 9672 |
| + | ---------------- | ||
(PCV10 price=20) | (PCV10 price=20) | ||
Revision as of 09:35, 21 August 2014
This page is a encyclopedia article.
The page identifier is Op_en6838 |
|---|
| Moderator:Nobody (see all) Click here to sign up. |
|
Give your opinion to the peer rating of the content of this page. |
| Upload data
|
The effects of alternative vaccine compositions on the outcomes of the cost-benefit analysis were assessed. Five modifications for PCV10 and one for PCV13 were considered
Conclusion: The assumption about serotype 3 in PCV13 is crucial. In addition, assumptions about the role of 6A in PCV10 is important.
PCV13adv.inIPD = (IPD under PCv10) - (IPD under PCV13) if positive, PCV13 saves IPD compared to PCV10
price of PCV13 = if PCV10 price set at 20e, what is the matching price for PCV13?
ICER
= incremental cost-effectiveness ratio for PCV10 at price 20e
(in this table, this value is also average cost per QALY)
rows: [1] pcv10 [2] pcv10 + 19A(direct effects only) [3] pcv10 + 6A [4] pcv10 + 19A(direct only) + 6A [5] pcv10 + 19A(full) [6] pcv10 + 19A(full) + 6A = PCV13 - 3
columns: [1] pcv13 - 3 (excluding serotype 3) [2] pcv13
PCV13adv.inIPD price of PCV13 ICER
============== ============== ===============
PCV13-3 PCV13 PCV13-3 PCV13 PCV13-3 PCV13
--- --- ------- ----- ----- ----
pcv10 12 150 18 38 8077 8077
pcv10+19Ad -2 134 17 37 7714 7714
pcv10+6A 50 188 25 55 13590 13590
pcv10+19Ad+6A 32 169 24 52 12724 12724
pcv10+19Af -31 105 15 32 6198 6199
pcv10+19Af+6A * 137 * 43 * 9672
----------------
(PCV10 price=20)
